PDCD1 and neoplasm: These samples, acquired from seven BCC patients, represent malignant, stromal, and immune cells present within the tumor microenvironment both before and after anti-programmed cell death protein 1 (PD-1) immunotherapy, and were profiled using scATAC-seq to generate chromatin accessibility profiles for 37,818 cells (10).